Brain-derived neurotrophic factor Val66Met polymorphism and cognitive function in persons with cardiovascular disease

Psychogeriatrics

Volumn 13, Issue 4, 2013, Pages 206-212

  Szabo, Ashley J ^a   Alosco, Michael L ^a   Miller, Lindsay A ^a   Mcgeary, John E ^b,c   Poppas, Athena ^d   Cohen, Ronald A ^b,e   Gunstad, John ^a  

^a KENT STATE UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Rhode Island Medical Center   (United States)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

BDNF; Cardiovascular disease; Cognitive function; Genetics; Met allele

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DNA; METHIONINE; VALINE;

ADULT; AGED; ALLELE; ARTICLE; ATTENTION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPTH PERCEPTION; EXECUTIVE FUNCTION; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; STROOP TEST; VERY ELDERLY;

BDNF; CARDIOVASCULAR DISEASE; COGNITIVE FUNCTION; GENETICS; MET ALLELE;

AGED; AGED, 80 AND OVER; ALLELES; ATTENTION; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CARDIOVASCULAR DISEASES; COGNITION; COGNITION DISORDERS; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GERIATRIC ASSESSMENT; HUMANS; MALE; MEMORY; METHIONINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; VALINE;

EID: 84897036354     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/psyg.12013     Document Type: Article

References (47)

1. Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: morbidity, mortality, and costs. Clin Geriatr Med 2009; 25: 563-577.
2. Zuccala G, Pedone C, Cesari M etal. The effects of cognitive impairment on mortality among hospitalized patients with heart failure. Am J Med 2003; 115: 97-103.
3. Peila R, White L, Masaki K, Petrovitch H, Launer L. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 2006; 37: 1165-1170.
4. Vogels R, Scheltens P, Schroeder-Tanka J, Weinstein H. Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail 2007; 9: 440-449.
5. Solomon A, Kareholt I, Ngandu T etal. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 2007; 68: 751-756.
6. Hogue CW, Hershey T, Dixon D etal. Preexisting cognitive impairment in women before cardiac surgery and its relationship with C-reactive protein concentrations. Anesth Analg 2006; 102: 1602-1608.
7. DeCarli C. Prevention of white-matter lesions through control of cerebrovascular risk factors. Int Psychogeriatr 2003; 15: 147-151.
8. Gianaros PJ, Greer PJ, Ryan CM, Jennings JR. Higher blood pressure predicts lower regional grey matter volume: consequences on short-term information processing. Neuroimage 2006; 31: 754-765.
9. Raz N, Rodrigue K, Kennedy K, Head D, Gunning-Dixon F, Acker J. Differential aging of the human striatum: longitudinal evidence. AJNR Am J Neuroradiol 2003; 24: 1849-1856.
10. Dufouil C, de Kersaint-Gilly A, Besançon V etal. Longitudinal study of blood pressure and white matter hyperintensity: the EVA MRI Cohort. Neurology 2001; 56: 921-926.
11. Veldnick J, Scheltens P, Jonker C, Launer L. Progression of cerebral white matter hyperintensities on MRI is related to diastolic blood pressure. Neurology 1998; 51: 319-320.
12. Haley A, Forman D, Poppas A etal. Carotid artery intima-media thickness and cognition in cardiovascular disease. Int J Cardiol 2007; 121: 148-154.
13. Moser DJ, Robinson RG, Hynes SM etal. Neuropsychological performance is associated with vascular function in patients with atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 141-146.
14. Jefferson A, Poppas A, Paul R, Cohen R. Systemic hypoperfusion is associated with executive dysfunction in geriatric cardiac patients. Neurobiol Aging 2007; 28: 477-483.
15. Jefferson AL, Massaro JM, Wolf A etal. Inflammatory biomarkers are associated with total brain volume: the Framington Heart Study. Neurology 2007; 68: 1032-1038.
16. Price JM, Hellermann A, Hellermann G, Sutton ET. Aging enhances vascular dysfunction induced by the Alzheimer's peptide beta-amyloid. Neurol Res 2004; 26: 305-311.
17. Connor B, Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res Brain Res Rev 1998; 27: 1-39.
18. Akatsu H, Yamagata H, Kawamata J etal. Variations in the BDNF gene in autopsy-confirmed Alzheimer's disease and dementia with Lewy bodies in Japan. Dement Geriatr Cogn Disord 2006; 22: 216-222.
19. Egan MF, Kojima M, Callicott JH etal. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003; 112: 257-269.
20. Erickson K, Kim J, Suever B, Voss M, Francis B, Kramer A. Genetic contributions to age-related decline in executive function: a 10-year longitudinal study of COMT and BDNF polymorphisms. Front Hum Neurosci 2008; 2: 11.
21. Schofield PR, Williams LM, Paul RH etal. Disturbances in selective information processing associated with the BDNF Val66Met polymorphism: evidence from cognition, the P300 and fronto-hippocampal systems. Biol Psychol 2009; 80: 176-188.
22. Gong P, Zheng A, Chen D. Effect of BDNF Val66Met polymorphism on digital working memory and spatial localization in a healthy Chinese Han population. J Mol Neurosci 2009; 38: 250-256.
23. Miyajima F, Ollier W. Brain-derived neurotrophic factor polymorphism Val66met influences cognitive abilities in the elderly. Genes Brain Behav 2008; 7: 411-417.
24. Li G, Peskind ER, Millard SP etal. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non- demented subjects. PLoS One 2009; 4: 1-5.
25. Komulainen P, Pedersen M, Hänninen T etal. BDNF is a novel marker of cognitive function in ageing women: the DR's EXTRA Study. Neurobiol Learn Mem 2008; 90: 606-613.
26. Fukumoto N, Fujii T, Combarros O etal. Sexually dimorphic effect of the Val66Met Polymorphism on susceptibility to Alzheimer's disease: new data and meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2010; 153b: 235-242.
27. Livak KJ, Marmaro J, Todd JA. Towards fully automated genome-wide polymorphism screening. Nat Genet 1995; 9: 341-342.
28. Teng E, Chui H. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 1987; 48: 314-318.
29. Mattis S. Dementia Rating Scale (DRS). Odessa, FL: Psychological Assessment Resources, 1988.
30. Reitan R, Wolfson D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, AZ: Neuropsychology Press, 1993.
31. Wechsler D. Wechsler Adult Intelligence Scale-III. San Antonio, TX: The Psychological Corporation, 1997.
32. Jensen AR, Rohwer WD. The Stroop Color-Word Test: a review. Acta Psychol (Amst) 1966; 25: 36-93.
33. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935; 18: 643-662.
34. Fastenau P, Denburg N, Hufford B. Adult norms for the Rey-Osterrieth Complex Figure Test and for supplemental recognition and matching trials from the Extended Complex Figure Test. Clin Neuropsychol 1999; 13: 30-47.
35. Hawkins KA, Sledge WH, Orleans JE, Quinlan DM, Rakfeldt J, Huffman RE. Normative implications of the relationship between reading vocabulary and Boston Naming Test performance. Arch Clin Neuropsychol 1993; 8: 525-537.
36. Benton AL, Hamsher K. Multilingual Aphasia Examination, 3rd edn. Iowa City, IA: AJA, 1989.
37. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. New York: Oxford University Press, 1991.
38. Morris J, Heyman A, Mohs R etal. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989; 39: 1159-1165.
39. Lezak MD. The test-retest stability and reliability of some tests commonly used in neuropsychological assessment. Paper presented at the 5th European conference of the International Neuropsychological Society, Deauville, France, 1982.
40. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment, 4th edn. New York: Oxford University Press, 2004.
41. Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998; 37: 1553-1561.
42. Golden E, Emiliano A, Maudsley S etal. Circulating brain-derived neurotrophic factor and indices of metabolic and cardiovascular health: data from the Baltimore Longitudinal Study of Aging. PLoS ONE 2010; 5: e10099.
43. Chaldakov GN, Fiore M, Stankulov IS etal. Neurotrophin presence in human coronary atherosclerosis and metabolic syndrome: a role for NGF and BDNF in cardiovascular disease? Prog Brain Res 2004; 146: 279-289.
44. Bath KG, Lee FS. Variant BDNF (Val66Met) impact on brain structure and function. Cogn Affect Behav Neurosci 2006; 6: 79-85.
45. Hashimoto R, Hirata Y, Asada T. Effect of the brain-derived neurotrophic factor and the apolipoprotein E polymorphisms on disease progression in preclinical Alzheimer's disease. Genes Brain Behav 2009; 8: 43-52.
46. Frodl T, Moller HJ, Meisenzah E. Neuroimaging genetics: new perspectives in research on major depression? Acta Psychiatr Scand 2008; 118: 363-372.
47. van Haren NE, Bakker SC, Kahn RS. Genes and structural brain imaging in schizophrenia. Curr Opin Psychiatry 2008; 21: 161-167.